8-K

Date: November 12, 2014

HORIZON PHARMA PUBLIC LIMITED COMPANY

/s/ Paul W. Hoelscher

Paul W. Hoelscher

Executive Vice President and Chief Financial Officer

0001193125-14-409205.txt : 20141112 0001193125-14-409205.hdr.sgml : 20141111 20141112160304 ACCESSION NUMBER: 0001193125-14-409205 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141110 ITEM INFORMATION: Other Events FILED AS OF DATE: 20141112 DATE AS OF CHANGE: 20141112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Pharma plc CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272179987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 141213916 BUSINESS ADDRESS: STREET 1: ADELAIDE CHAMBERS STREET 2: PETER STREET CITY: DUBLIN STATE: L2 ZIP: 8 BUSINESS PHONE: 011-353-1-649-8521 MAIL ADDRESS: STREET 1: ADELAIDE CHAMBERS STREET 2: PETER STREET CITY: DUBLIN STATE: L2 ZIP: 8 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 8-K 1 d820519d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2014

Horizon Pharma Public Limited Company

(Exact name of registrant as specified in its charter)


Ireland	001-35238	Not Applicable

(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

Adelaide Chambers, Peter Street, Dublin 8, Ireland

(Address of principal executive offices)

Registrant’s telephone number, including area code: 011-353-1-649-8521

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other

Events.

On November 10, 2014, Judge Joseph E. Irenas of the United States District Court for the District of New Jersey issued a “Markman” claim construction ruling in the on-going patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc. for an Abbreviated New Drug Application (ANDA) to market a generic version of RAYOS^®. A Markman claim construction ruling is a determination by the court of the meaning and scope of disputed patent claim terms of certain patents in suit. Judge Irenas was asked to construe disputed claim terms in U.S. Patent No. 8,394,407 and U.S. Patent No. 8,309,124 and adopted Horizon’s proposed construction of both of the disputed claim terms.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.